This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Cheryl Cohen Biography and Net Worth

Director of ImmunityBio

Cheryl L. Cohen is on the board of Aerpio Therapeutics, Inc. and 4 other companies.

In her past career Ms. Cohen held the position of President of CLC Consulting LLC, Vice President-Strategic Commercial Group at Health Care Systems, Inc., Vice President-Rheumatology Franchise at Centocor, Inc., Principal at Solvay Pharmaceuticals, Inc., Chief Commercial Officer of Medivation LLC (California) and Vice President for Janssen Biotech, Inc.

Cheryl L. Cohen received an undergraduate degree from Saint Joseph College.

What is Cheryl Cohen's net worth?: The estimated net worth of Cheryl Cohen is at least $967,226.82 as of August 20th, 2021. Ms. Cohen owns 215,418 shares of ImmunityBio stock worth more than $967,227 as of November 16th. This net worth evaluation does not reflect any other investments that Ms. Cohen may own. Learn More about Cheryl Cohen's net worth.
How do I contact Cheryl Cohen?: The corporate mailing address for Ms. Cohen and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Cheryl Cohen's contact information.
Has Cheryl Cohen been buying or selling shares of ImmunityBio?: Cheryl Cohen has not been actively trading shares of ImmunityBio in the last ninety days. Most recently, Cheryl Cohen sold 14,801 shares of the business's stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $10.12, for a transaction totalling $149,786.12. Following the completion of the sale, the director now directly owns 215,418 shares of the company's stock, valued at $2,180,030.16. Learn More on Cheryl Cohen's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.

Cheryl Cohen Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2021	Sell	14,801	$10.12	$149,786.12	215,418
8/20/2021	Sell	9,976	$10.00	$99,760.00	215,418
8/17/2021	Sell	43,398	$10.12	$439,187.76

Cheryl Cohen Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Today's Range

Now: $4.49

$4.43

$4.94

50 Day Range

MA: $4.12

$3.23

$6.17

2 Week Range

Now: $4.49

$3.10

$10.53

Volume

5,135,577 shs

Average Volume

4,984,939 shs

Market Capitalization

$3.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

There is a little known company that is changing warfare

From Reticulate | Ad

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t